200 related articles for article (PubMed ID: 31764175)
61. The alternative splicing regulator Tra2b is required for somitogenesis and regulates splicing of an inhibitory Wnt11b isoform.
Dichmann DS; Walentek P; Harland RM
Cell Rep; 2015 Feb; 10(4):527-36. PubMed ID: 25620705
[TBL] [Abstract][Full Text] [Related]
62. [A progress toward research on alternative splicing of genes in tumor cells].
Zhou ZR; Sun KL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):177-80. PubMed ID: 16604490
[TBL] [Abstract][Full Text] [Related]
63. Alternative splicing as a biomarker and potential target for drug discovery.
Le KQ; Prabhakar BS; Hong WJ; Li LC
Acta Pharmacol Sin; 2015 Oct; 36(10):1212-8. PubMed ID: 26073330
[TBL] [Abstract][Full Text] [Related]
64. MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.
Liu L; Luo C; Luo Y; Chen L; Liu Y; Wang Y; Han J; Zhang Y; Wei N; Xie Z; Wu W; Wu G; Feng Y
Oncogene; 2018 Jan; 37(1):86-94. PubMed ID: 28869607
[TBL] [Abstract][Full Text] [Related]
65. RNA mis-splicing in disease.
Scotti MM; Swanson MS
Nat Rev Genet; 2016 Jan; 17(1):19-32. PubMed ID: 26593421
[TBL] [Abstract][Full Text] [Related]
66. Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing.
Li T; Liu Q; Garza N; Kornblau S; Jin VX
Genome Med; 2018 Apr; 10(1):30. PubMed ID: 29665865
[TBL] [Abstract][Full Text] [Related]
67. We skip to work: alternative splicing in normal and malignant myelopoiesis.
Wong ACH; Rasko JEJ; Wong JJ
Leukemia; 2018 May; 32(5):1081-1093. PubMed ID: 29467484
[TBL] [Abstract][Full Text] [Related]
68. Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.
Adamia S; Kriangkum J; Belch AR; Pilarski LM
Adv Cancer Res; 2014; 123():67-94. PubMed ID: 25081526
[TBL] [Abstract][Full Text] [Related]
69. Autophagy regulation by RNA alternative splicing and implications in human diseases.
González-Rodríguez P; Klionsky DJ; Joseph B
Nat Commun; 2022 May; 13(1):2735. PubMed ID: 35585060
[TBL] [Abstract][Full Text] [Related]
70. Hypoxia alters splicing of the cancer associated Fas gene.
Peciuliene I; Vilys L; Jakubauskiene E; Zaliauskiene L; Kanopka A
Exp Cell Res; 2019 Jul; 380(1):29-35. PubMed ID: 31002816
[TBL] [Abstract][Full Text] [Related]
71. Alternative splicing and the proteome.
Cottingham K
J Proteome Res; 2004; 3(1):17. PubMed ID: 14998157
[No Abstract] [Full Text] [Related]
72. Alternative splicing events and function in the tumor microenvironment: New opportunities and challenges.
Song X; Li X; Ge Y; Song J; Wei Q; He M; Wei M; Zhang Y; Chen T; Zhao L
Int Immunopharmacol; 2023 Oct; 123():110718. PubMed ID: 37597404
[TBL] [Abstract][Full Text] [Related]
73. Analysis of alternative splicing events for cancer diagnosis using a multiplexing nanophotonic biosensor.
Huertas CS; Domínguez-Zotes S; Lechuga LM
Sci Rep; 2017 Jan; 7():41368. PubMed ID: 28120920
[TBL] [Abstract][Full Text] [Related]
74. Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation.
Pagliarini V; Naro C; Sette C
Biomed Res Int; 2015; 2015():543067. PubMed ID: 26273627
[TBL] [Abstract][Full Text] [Related]
75. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.
Farina AR; Cappabianca L; Sebastiano M; Zelli V; Guadagni S; Mackay AR
J Exp Clin Cancer Res; 2020 Jun; 39(1):110. PubMed ID: 32536347
[TBL] [Abstract][Full Text] [Related]
76. A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients.
Cheng R; Xiao L; Zhou W; Jin X; Xu Z; Xu C; Wang P; Luo M; Wang M; Ma K; Cao H; Huang Y; Lin X; Pang F; Li Y; Jiang Q
Oncogene; 2021 Sep; 40(35):5441-5450. PubMed ID: 34285345
[TBL] [Abstract][Full Text] [Related]
77. Alternative splicing and protein interaction data sets.
Talavera D; Robertson DL; Lovell SC
Nat Biotechnol; 2013 Apr; 31(4):292-3. PubMed ID: 23563420
[No Abstract] [Full Text] [Related]
78. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.
Bonomi S; Gallo S; Catillo M; Pignataro D; Biamonti G; Ghigna C
Int J Cell Biol; 2013; 2013():962038. PubMed ID: 24285959
[TBL] [Abstract][Full Text] [Related]
79. Contribution of alternative splicing to breast cancer metastasis.
Meng X; Yang S; Zhang J; Yu H
J Cancer Metastasis Treat; 2019; 5():. PubMed ID: 31737791
[TBL] [Abstract][Full Text] [Related]
80. Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.
Solomon H; Sharon M; Rotter V
Cell Death Differ; 2014 Sep; 21(9):1347-9. PubMed ID: 25109594
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
